{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T17:14:54Z","timestamp":1773076494895,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["Grant No. 2023ZD0502105"],"award-info":[{"award-number":["Grant No. 2023ZD0502105"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["Grant No. 2023ZD0502105"],"award-info":[{"award-number":["Grant No. 2023ZD0502105"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["Grant No. 2023ZD0502105"],"award-info":[{"award-number":["Grant No. 2023ZD0502105"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["Grant No. 2023ZD0502105"],"award-info":[{"award-number":["Grant No. 2023ZD0502105"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["Grant No. 2023ZD0502105"],"award-info":[{"award-number":["Grant No. 2023ZD0502105"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["Grant No. 2023ZD0502105"],"award-info":[{"award-number":["Grant No. 2023ZD0502105"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["Grant No. 2023ZD0502105"],"award-info":[{"award-number":["Grant No. 2023ZD0502105"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["Grant No. 2023ZD0502105"],"award-info":[{"award-number":["Grant No. 2023ZD0502105"]}]},{"name":"Chunhui program of the MOE","award":["Grant No. HZKY20220231"],"award-info":[{"award-number":["Grant No. HZKY20220231"]}]},{"name":"Chunhui program of the MOE","award":["Grant No. HZKY20220231"],"award-info":[{"award-number":["Grant No. HZKY20220231"]}]},{"name":"Chunhui program of the MOE","award":["Grant No. HZKY20220231"],"award-info":[{"award-number":["Grant No. HZKY20220231"]}]},{"name":"Chunhui program of the MOE","award":["Grant No. HZKY20220231"],"award-info":[{"award-number":["Grant No. HZKY20220231"]}]},{"name":"Chunhui program of the MOE","award":["Grant No. HZKY20220231"],"award-info":[{"award-number":["Grant No. HZKY20220231"]}]},{"name":"Chunhui program of the MOE","award":["Grant No. HZKY20220231"],"award-info":[{"award-number":["Grant No. HZKY20220231"]}]},{"name":"Chunhui program of the MOE","award":["Grant No. HZKY20220231"],"award-info":[{"award-number":["Grant No. HZKY20220231"]}]},{"name":"Chunhui program of the MOE","award":["Grant No. HZKY20220231"],"award-info":[{"award-number":["Grant No. HZKY20220231"]}]},{"name":"MOE Liberal arts and Social Sciences Foundation","award":["Grant No. 24YJCZH462"],"award-info":[{"award-number":["Grant No. 24YJCZH462"]}]},{"name":"MOE Liberal arts and Social Sciences Foundation","award":["Grant No. 24YJCZH462"],"award-info":[{"award-number":["Grant No. 24YJCZH462"]}]},{"name":"MOE Liberal arts and Social Sciences Foundation","award":["Grant No. 24YJCZH462"],"award-info":[{"award-number":["Grant No. 24YJCZH462"]}]},{"name":"MOE Liberal arts and Social Sciences Foundation","award":["Grant No. 24YJCZH462"],"award-info":[{"award-number":["Grant No. 24YJCZH462"]}]},{"name":"MOE Liberal arts and Social Sciences Foundation","award":["Grant No. 24YJCZH462"],"award-info":[{"award-number":["Grant No. 24YJCZH462"]}]},{"name":"MOE Liberal arts and Social Sciences Foundation","award":["Grant No. 24YJCZH462"],"award-info":[{"award-number":["Grant No. 24YJCZH462"]}]},{"name":"MOE Liberal arts and Social Sciences Foundation","award":["Grant No. 24YJCZH462"],"award-info":[{"award-number":["Grant No. 24YJCZH462"]}]},{"name":"MOE Liberal arts and Social Sciences Foundation","award":["Grant No. 24YJCZH462"],"award-info":[{"award-number":["Grant No. 24YJCZH462"]}]},{"name":"the Natural Science Foundation of Guizhou Province","award":["Grant No. ZK2022-YB632"],"award-info":[{"award-number":["Grant No. ZK2022-YB632"]}]},{"name":"the Natural Science Foundation of Guizhou Province","award":["Grant No. ZK2022-YB632"],"award-info":[{"award-number":["Grant No. ZK2022-YB632"]}]},{"name":"the Natural Science Foundation of Guizhou Province","award":["Grant No. ZK2022-YB632"],"award-info":[{"award-number":["Grant No. ZK2022-YB632"]}]},{"name":"the Natural Science Foundation of Guizhou Province","award":["Grant No. ZK2022-YB632"],"award-info":[{"award-number":["Grant No. ZK2022-YB632"]}]},{"name":"the Natural Science Foundation of Guizhou Province","award":["Grant No. ZK2022-YB632"],"award-info":[{"award-number":["Grant No. ZK2022-YB632"]}]},{"name":"the Natural Science Foundation of Guizhou Province","award":["Grant No. ZK2022-YB632"],"award-info":[{"award-number":["Grant No. ZK2022-YB632"]}]},{"name":"the Natural Science Foundation of Guizhou Province","award":["Grant No. ZK2022-YB632"],"award-info":[{"award-number":["Grant No. ZK2022-YB632"]}]},{"name":"the Natural Science Foundation of Guizhou Province","award":["Grant No. ZK2022-YB632"],"award-info":[{"award-number":["Grant No. ZK2022-YB632"]}]},{"name":"Youth Talent Project of Guizhou Provincial Department of Education","award":["Grant No. QJJ2022-224"],"award-info":[{"award-number":["Grant No. QJJ2022-224"]}]},{"name":"Youth Talent Project of Guizhou Provincial Department of Education","award":["Grant No. QJJ2022-224"],"award-info":[{"award-number":["Grant No. QJJ2022-224"]}]},{"name":"Youth Talent Project of Guizhou Provincial Department of Education","award":["Grant No. QJJ2022-224"],"award-info":[{"award-number":["Grant No. QJJ2022-224"]}]},{"name":"Youth Talent Project of Guizhou Provincial Department of Education","award":["Grant No. QJJ2022-224"],"award-info":[{"award-number":["Grant No. QJJ2022-224"]}]},{"name":"Youth Talent Project of Guizhou Provincial Department of Education","award":["Grant No. QJJ2022-224"],"award-info":[{"award-number":["Grant No. QJJ2022-224"]}]},{"name":"Youth Talent Project of Guizhou Provincial Department of Education","award":["Grant No. QJJ2022-224"],"award-info":[{"award-number":["Grant No. QJJ2022-224"]}]},{"name":"Youth Talent Project of Guizhou Provincial Department of Education","award":["Grant No. QJJ2022-224"],"award-info":[{"award-number":["Grant No. QJJ2022-224"]}]},{"name":"Youth Talent Project of Guizhou Provincial Department of Education","award":["Grant No. QJJ2022-224"],"award-info":[{"award-number":["Grant No. QJJ2022-224"]}]},{"name":"China Lung Cancer Immunotherapy Research Project, Excellent Young Talent Cultivation Project of Zunyi City","award":["Zunshi Kehe HZ (2023) 142"],"award-info":[{"award-number":["Zunshi Kehe HZ (2023) 142"]}]},{"name":"China Lung Cancer Immunotherapy Research Project, Excellent Young Talent Cultivation Project of Zunyi City","award":["Zunshi Kehe HZ (2023) 142"],"award-info":[{"award-number":["Zunshi Kehe HZ (2023) 142"]}]},{"name":"China Lung Cancer Immunotherapy Research Project, Excellent Young Talent Cultivation Project of Zunyi City","award":["Zunshi Kehe HZ (2023) 142"],"award-info":[{"award-number":["Zunshi Kehe HZ (2023) 142"]}]},{"name":"China Lung Cancer Immunotherapy Research Project, Excellent Young Talent Cultivation Project of Zunyi City","award":["Zunshi Kehe HZ (2023) 142"],"award-info":[{"award-number":["Zunshi Kehe HZ (2023) 142"]}]},{"name":"China Lung Cancer Immunotherapy Research Project, Excellent Young Talent Cultivation Project of Zunyi City","award":["Zunshi Kehe HZ (2023) 142"],"award-info":[{"award-number":["Zunshi Kehe HZ (2023) 142"]}]},{"name":"China Lung Cancer Immunotherapy Research Project, Excellent Young Talent Cultivation Project of Zunyi City","award":["Zunshi Kehe HZ (2023) 142"],"award-info":[{"award-number":["Zunshi Kehe HZ (2023) 142"]}]},{"name":"China Lung Cancer Immunotherapy Research Project, Excellent Young Talent Cultivation Project of Zunyi City","award":["Zunshi Kehe HZ (2023) 142"],"award-info":[{"award-number":["Zunshi Kehe HZ (2023) 142"]}]},{"name":"China Lung Cancer Immunotherapy Research Project, Excellent Young Talent Cultivation Project of Zunyi City","award":["Zunshi Kehe HZ (2023) 142"],"award-info":[{"award-number":["Zunshi Kehe HZ (2023) 142"]}]},{"name":"Future Science and Technology Elite Talent Cultivation Project of Zunyi Medical University","award":["ZYSE 2023-02"],"award-info":[{"award-number":["ZYSE 2023-02"]}]},{"name":"Future Science and Technology Elite Talent Cultivation Project of Zunyi Medical University","award":["ZYSE 2023-02"],"award-info":[{"award-number":["ZYSE 2023-02"]}]},{"name":"Future Science and Technology Elite Talent Cultivation Project of Zunyi Medical University","award":["ZYSE 2023-02"],"award-info":[{"award-number":["ZYSE 2023-02"]}]},{"name":"Future Science and Technology Elite Talent Cultivation Project of Zunyi Medical University","award":["ZYSE 2023-02"],"award-info":[{"award-number":["ZYSE 2023-02"]}]},{"name":"Future Science and Technology Elite Talent Cultivation Project of Zunyi Medical University","award":["ZYSE 2023-02"],"award-info":[{"award-number":["ZYSE 2023-02"]}]},{"name":"Future Science and Technology Elite Talent Cultivation Project of Zunyi Medical University","award":["ZYSE 2023-02"],"award-info":[{"award-number":["ZYSE 2023-02"]}]},{"name":"Future Science and Technology Elite Talent Cultivation Project of Zunyi Medical University","award":["ZYSE 2023-02"],"award-info":[{"award-number":["ZYSE 2023-02"]}]},{"name":"Future Science and Technology Elite Talent Cultivation Project of Zunyi Medical University","award":["ZYSE 2023-02"],"award-info":[{"award-number":["ZYSE 2023-02"]}]},{"name":"the Key Program of the Education Sciences Planning of Guizhou Province","award":["Grant No.7"],"award-info":[{"award-number":["Grant No.7"]}]},{"name":"the Key Program of the Education Sciences Planning of Guizhou Province","award":["Grant No.7"],"award-info":[{"award-number":["Grant No.7"]}]},{"name":"the Key Program of the Education Sciences Planning of Guizhou Province","award":["Grant No.7"],"award-info":[{"award-number":["Grant No.7"]}]},{"name":"the Key Program of the Education Sciences Planning of Guizhou Province","award":["Grant No.7"],"award-info":[{"award-number":["Grant No.7"]}]},{"name":"the Key Program of the Education Sciences Planning of Guizhou Province","award":["Grant No.7"],"award-info":[{"award-number":["Grant No.7"]}]},{"name":"the Key Program of the Education Sciences Planning of Guizhou Province","award":["Grant No.7"],"award-info":[{"award-number":["Grant No.7"]}]},{"name":"the Key Program of the Education Sciences Planning of Guizhou Province","award":["Grant No.7"],"award-info":[{"award-number":["Grant No.7"]}]},{"name":"the Key Program of the Education Sciences Planning of Guizhou Province","award":["Grant No.7"],"award-info":[{"award-number":["Grant No.7"]}]},{"name":"Collaborative Innovation Center of Chinese Ministry of Education","award":["Grant No. 2020-39"],"award-info":[{"award-number":["Grant No. 2020-39"]}]},{"name":"Collaborative Innovation Center of Chinese Ministry of Education","award":["Grant No. 2020-39"],"award-info":[{"award-number":["Grant No. 2020-39"]}]},{"name":"Collaborative Innovation Center of Chinese Ministry of Education","award":["Grant No. 2020-39"],"award-info":[{"award-number":["Grant No. 2020-39"]}]},{"name":"Collaborative Innovation Center of Chinese Ministry of Education","award":["Grant No. 2020-39"],"award-info":[{"award-number":["Grant No. 2020-39"]}]},{"name":"Collaborative Innovation Center of Chinese Ministry of Education","award":["Grant No. 2020-39"],"award-info":[{"award-number":["Grant No. 2020-39"]}]},{"name":"Collaborative Innovation Center of Chinese Ministry of Education","award":["Grant No. 2020-39"],"award-info":[{"award-number":["Grant No. 2020-39"]}]},{"name":"Collaborative Innovation Center of Chinese Ministry of Education","award":["Grant No. 2020-39"],"award-info":[{"award-number":["Grant No. 2020-39"]}]},{"name":"Collaborative Innovation Center of Chinese Ministry of Education","award":["Grant No. 2020-39"],"award-info":[{"award-number":["Grant No. 2020-39"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15060-5","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T13:27:55Z","timestamp":1760448475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of brain radiotherapy combined with atezolizumab and platinum-doublet chemotherapy for advanced non-small-cell lung cancer with brain metastases: a pooled analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Quan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzhu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"5","key":"15060_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41571-019-0320-3","volume":"17","author":"JH Suh","year":"2020","unstructured":"Suh JH, Kotecha R, Chao ST, Ahluwalia MS, Sahgal A, Chang EL. Current approaches to the management of brain metastases. Nat Rev Clin Oncol. 2020;17(5):279\u201399.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"15060_CR2","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1038\/s41467-023-40793-x","volume":"14","author":"A Skakodub","year":"2023","unstructured":"Skakodub A, Walch H, Tringale KR, Eichholz J, Imber BS, Vasudevan HN, et al. Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis. Nat Commun. 2023;14(1):4980.","journal-title":"Nat Commun"},{"issue":"12","key":"15060_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","volume":"18","author":"CS Gillespie","year":"2023","unstructured":"Gillespie CS, Mustafa MA, Richardson GE, Alam AM, Lee KS, Hughes DM, et al. Genomic alterations and the incidence of brain metastases in advanced and metastatic NSCLC: a systematic review and meta-analysis. J Thorac Oncol. 2023;18(12):1703\u201313.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"15060_CR4","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","volume":"19","author":"DN Cagney","year":"2017","unstructured":"Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19(11):1511\u201321.","journal-title":"Neuro Oncol"},{"issue":"3","key":"15060_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ijrobp.2009.08.025","volume":"77","author":"PW Sperduto","year":"2010","unstructured":"Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655\u201361.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15060_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ctrv.2016.03.009","volume":"45","author":"S Peters","year":"2016","unstructured":"Peters S, Bexelius C, Munk V, Leighl N. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev. 2016;45:139\u201362.","journal-title":"Cancer Treat Rev"},{"key":"15060_CR7","doi-asserted-by":"publisher","first-page":"829451","DOI":"10.3389\/fimmu.2022.829451","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Chen R, Wa Y, Ding S, Yang Y, Liao J, et al. Tumor immune microenvironment and immunotherapy in brain metastasis from non-small cell lung cancer. Front Immunol. 2022;13:829451.","journal-title":"Front Immunol"},{"issue":"4","key":"15060_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, et al. Non-Small cell lung Cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(4):249\u201374.","journal-title":"J Natl Compr Canc Netw"},{"issue":"22","key":"15060_CR9","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic Non-Small-Cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"16","key":"15060_CR10","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-20-0798","volume":"26","author":"I Eguren-Santamaria","year":"2020","unstructured":"Eguren-Santamaria I, Sanmamed MF, Goldberg SB, Kluger HM, Idoate MA, Lu BY, et al. PD-1\/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice. Clin Cancer Res. 2020;26(16):4186\u201397.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"15060_CR11","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"2","key":"15060_CR12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198\u2013211.","journal-title":"Lancet Oncol"},{"issue":"21","key":"15060_CR13","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020\u201331.","journal-title":"N Engl J Med"},{"issue":"2","key":"15060_CR14","doi-asserted-by":"publisher","first-page":"765","DOI":"10.7150\/ijbs.91295","volume":"20","author":"W Shi","year":"2024","unstructured":"Shi W, Tanzhu G, Chen L, Ning J, Wang H, Xiao G, et al. Radiotherapy in preclinical models of brain metastases: a review and recommendations for future studies. Int J Biol Sci. 2024;20(2):765\u201383.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"15060_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","volume":"9","author":"W Theelen","year":"2021","unstructured":"Theelen W, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts J, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021;9(5):467\u201375.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"15060_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bbadis.2010.07.019","volume":"1812","author":"DW Holman","year":"2011","unstructured":"Holman DW, Klein RS, Ransohoff RM. The blood-brain barrier, chemokines and multiple sclerosis. Biochim Biophys Acta. 2011;1812(2):220\u201330.","journal-title":"Biochim Biophys Acta"},{"key":"15060_CR17","doi-asserted-by":"publisher","first-page":"217133","DOI":"10.1016\/j.canlet.2024.217133","volume":"598","author":"J Li","year":"2024","unstructured":"Li J, Bai M, Jia W, Zhai X, Wang M, Yu J, et al. Irradiated tumor cell-released microparticles enhance the therapeutic efficacy of PD-1 inhibitors by promoting M1-TAMs polarization in NSCLC brain metastases. Cancer Lett. 2024;598:217133.","journal-title":"Cancer Lett"},{"issue":"4","key":"15060_CR18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jtho.2018.01.012","volume":"13","author":"HG Hubbeling","year":"2018","unstructured":"Hubbeling HG, Schapira EF, Horick NK, Goodwin KEH, Lin JJ, Oh KS, et al. Safety of combined PD-1 pathway inhibition and intracranial radiation therapy in non-small cell lung cancer. J Thorac Oncol. 2018;13(4):550\u20138.","journal-title":"J Thorac Oncol"},{"issue":"15","key":"15060_CR19","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1002\/cncr.35242","volume":"130","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Guo T, Liang F, Wang Z, Zhang J, Ni J, et al. Cumulative incidence and risk factors of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150. Cancer. 2024;130(15):2601\u201310.","journal-title":"Cancer"},{"issue":"7","key":"15060_CR20","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924\u201337.","journal-title":"Lancet Oncol"},{"issue":"13","key":"15060_CR21","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1158\/1078-0432.CCR-22-0471","volume":"28","author":"TGN Ton","year":"2022","unstructured":"Ton TGN, Pal N, Trinh H, Mahrus S, Bretscher MT, Machado RJM, et al. Replication of overall survival, progression-free survival, and overall response in chemotherapy arms of non-small cell lung cancer trials using real-world data. Clin Cancer Res. 2022;28(13):2844\u201353.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"15060_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","volume":"17","author":"N Nogami","year":"2022","unstructured":"Nogami N, Barlesi F, Socinski MA, Reck M, Thomas CA, Cappuzzo F, et al. IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain. J Thorac Oncol. 2022;17(2):309\u201323.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"15060_CR23","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"15060_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jtho.2021.08.019","volume":"17","author":"CM Bestvina","year":"2022","unstructured":"Bestvina CM, Pointer KB, Karrison T, Al-Hallaq H, Hoffman PC, Jelinek MJ, et al. A phase 1 trial of concurrent or sequential Ipilimumab, Nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study. J Thorac Oncol. 2022;17(1):130\u201340.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"15060_CR25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/BSD.0000000000000932","volume":"33","author":"LT Kane","year":"2020","unstructured":"Kane LT, Fang T, Galetta MS, Goyal DKC, Nicholson KJ, Kepler CK, et al. Propensity score matching: a statistical method. Clinical Spine Surgery: A Spine Publication. 2020;33(3):120\u20132.","journal-title":"Clinical Spine Surgery: A Spine Publication"},{"issue":"6","key":"15060_CR26","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/j.jtho.2020.11.030","volume":"16","author":"J Liang","year":"2021","unstructured":"Liang J, Hu Z, Zhan C, Wang Q. Using propensity score matching to balance the baseline characteristics. J Thorac Oncol. 2021;16(6):e45\u20136.","journal-title":"J Thorac Oncol"},{"key":"15060_CR27","doi-asserted-by":"crossref","unstructured":"van der Woude LL, Gorris MAJ, Wortel IMN, Creemers JHA, Verrijp K, Monkhorst K, et al. Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination. J Immunother Cancer. 2022;10(10).","DOI":"10.1136\/jitc-2022-005248"},{"issue":"1","key":"15060_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S1470-2045(24)00643-0","volume":"26","author":"Y Xu","year":"2025","unstructured":"Xu Y, Chen K, Xu Y, Li H, Huang Z, Lu H, et al. Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2025;26(1):74\u201384.","journal-title":"Lancet Oncol"},{"issue":"28","key":"15060_CR29","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1200\/JCO.22.02561","volume":"41","author":"E Nadal","year":"2023","unstructured":"Nadal E, Rodr\u00edguez-Abreu D, Sim\u00f3 M, Massut\u00ed B, Juan O, Huidobro G, et al. Phase II trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non-small-cell lung cancer with untreated brain metastases (Atezo-Brain, GECP17\/05). J Clin Oncol. 2023;41(28):4478\u201385.","journal-title":"J Clin Oncol"},{"issue":"4","key":"15060_CR30","first-page":"100655","volume":"5","author":"T Tozuka","year":"2024","unstructured":"Tozuka T, Minegishi Y, Yamaguchi O, Watanabe K, Toi Y, Saito R, et al. Immunotherapy with radiotherapy for brain metastases in patients with NSCLC: nej060. JTO Clin Res Rep. 2024;5(4):100655.","journal-title":"JTO Clin Res Rep"},{"issue":"8","key":"15060_CR31","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","volume":"20","author":"L Galluzzi","year":"2023","unstructured":"Galluzzi L, Aryankalayil MJ, Coleman CN, Formenti SC. Emerging evidence for adapting radiotherapy to immunotherapy. Nat Rev Clin Oncol. 2023;20(8):543\u201357.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"15060_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/pcmedi\/pbz004","volume":"2","author":"H Yang","year":"2019","unstructured":"Yang H, Jin T, Li M, Xue J, Lu B. Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges. Precis Clin Med. 2019;2(1):57\u201370.","journal-title":"Precis Clin Med"},{"issue":"6","key":"15060_CR33","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/1078-0432.CCR-16-1432","volume":"23","author":"C Tang","year":"2017","unstructured":"Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, et al. Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells. Clin Cancer Res. 2017;23(6):1388\u201396.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"15060_CR34","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/neuonc\/noab129","volume":"23","author":"S Scoccianti","year":"2021","unstructured":"Scoccianti S, Olmetto E, Pinzi V, Osti MF, Di Franco R, Caini S, et al. Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO. Neuro Oncol. 2021;23(10):1750\u201364.","journal-title":"Neuro Oncol"},{"key":"15060_CR35","first-page":"1193075","volume":"2022","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Zhou S, Yin H, Zhu C, Li D, Li X. Analysis of immunotherapy combined with radiotherapy in patients with brain metastasis of driver gene-negative non-small-cell lung cancer. Evid Based Complement Alternat Med. 2022;2022:1193075.","journal-title":"Evid Based Complement Alternat Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15060-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15060-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15060-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T13:28:06Z","timestamp":1760448486000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15060-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15060"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15060-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a retrospective pooled analysis of existing clinical trial data and was conducted in accordance with the ethical principles of the Declaration of Helsinki. As this research involved secondary analysis of anonymized data, the Institutional Review Board of the Second Affiliated Hospital, Zunyi Medical University (No. YXLL(KY-R)-2021-010) approved the study and waived the requirement for written informed consent, deeming it to be of negligible risk. The original trials from which data were pooled had obtained independent ethics committee approvals and complied with the Declaration of Helsinki, including appropriate informed consent procedures for primary data collection. No potentially identifiable images or data are included in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Ma has served as a consultant for Merck Serono, MSD, BMS and has received research support from Merck Serono, MSD, AstraZeneca, Novartis, BMS, and Teva. Other authors declares no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1568"}}